Global Generic Medicine 麻豆原创 Research Report 2024

Publication ID:

PB506245127

Publication Date:

June 20, 2024

Pages:

107

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Generic Medicine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Generic Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Medicine.
Report Scope
The Generic Medicine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Generic Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Generic Medicine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Segment by Type
Simple Generic Drugs
Super Generic Drugs
Biosimilars
By Application:
CNS
Cardiovascular
Respiratory
Rheumatology
Diabetes
Oncology
Segment by Application
CNS
Cardiovascular
Respiratory
Rheumatology
Diabetes
Oncology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Generic Medicine companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Generic Medicine 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Simple Generic Drugs
1.2.3 Super Generic Drugs
1.2.4 Biosimilars
1.2.5 By Application:
1.2.6 CNS
1.2.7 Cardiovascular
1.2.8 Respiratory
1.2.9 Rheumatology
1.2.10 Diabetes
1.2.11 Oncology
1.3 麻豆原创 by Application
1.3.1 Global Generic Medicine 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 CNS
1.3.3 Cardiovascular
1.3.4 Respiratory
1.3.5 Rheumatology
1.3.6 Diabetes
1.3.7 Oncology
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Generic Medicine 麻豆原创 Perspective (2019-2030)
2.2 Generic Medicine Growth Trends by Region
2.2.1 Global Generic Medicine 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Generic Medicine Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Generic Medicine Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Generic Medicine 麻豆原创 Dynamics
2.3.1 Generic Medicine Industry Trends
2.3.2 Generic Medicine 麻豆原创 Drivers
2.3.3 Generic Medicine 麻豆原创 Challenges
2.3.4 Generic Medicine 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Generic Medicine Players by Revenue
3.1.1 Global Top Generic Medicine Players by Revenue (2019-2024)
3.1.2 Global Generic Medicine Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Generic Medicine 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Generic Medicine Revenue
3.4 Global Generic Medicine 麻豆原创 Concentration Ratio
3.4.1 Global Generic Medicine 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Generic Medicine Revenue in 2023
3.5 Generic Medicine Key Players Head office and Area Served
3.6 Key Players Generic Medicine Product Solution and Service
3.7 Date of Enter into Generic Medicine 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Generic Medicine Breakdown Data by Type
4.1 Global Generic Medicine Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Generic Medicine Forecasted 麻豆原创 Size by Type (2025-2030)
5 Generic Medicine Breakdown Data by Application
5.1 Global Generic Medicine Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Generic Medicine Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Generic Medicine 麻豆原创 Size (2019-2030)
6.2 North America Generic Medicine 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Generic Medicine 麻豆原创 Size by Country (2019-2024)
6.4 North America Generic Medicine 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Generic Medicine 麻豆原创 Size (2019-2030)
7.2 Europe Generic Medicine 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Generic Medicine 麻豆原创 Size by Country (2019-2024)
7.4 Europe Generic Medicine 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Generic Medicine 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Generic Medicine 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Generic Medicine 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Generic Medicine 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Generic Medicine 麻豆原创 Size (2019-2030)
9.2 Latin America Generic Medicine 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Generic Medicine 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Generic Medicine 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Generic Medicine 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Generic Medicine 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Generic Medicine 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Generic Medicine 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Detail
11.1.2 Teva Business Overview
11.1.3 Teva Generic Medicine Introduction
11.1.4 Teva Revenue in Generic Medicine Business (2019-2024)
11.1.5 Teva Recent Development
11.2 Novartis - Sandoz
11.2.1 Novartis - Sandoz Company Detail
11.2.2 Novartis - Sandoz Business Overview
11.2.3 Novartis - Sandoz Generic Medicine Introduction
11.2.4 Novartis - Sandoz Revenue in Generic Medicine Business (2019-2024)
11.2.5 Novartis - Sandoz Recent Development
11.3 Mylan
11.3.1 Mylan Company Detail
11.3.2 Mylan Business Overview
11.3.3 Mylan Generic Medicine Introduction
11.3.4 Mylan Revenue in Generic Medicine Business (2019-2024)
11.3.5 Mylan Recent Development
11.4 Sun Pharmaceutical
11.4.1 Sun Pharmaceutical Company Detail
11.4.2 Sun Pharmaceutical Business Overview
11.4.3 Sun Pharmaceutical Generic Medicine Introduction
11.4.4 Sun Pharmaceutical Revenue in Generic Medicine Business (2019-2024)
11.4.5 Sun Pharmaceutical Recent Development
11.5 Aspen
11.5.1 Aspen Company Detail
11.5.2 Aspen Business Overview
11.5.3 Aspen Generic Medicine Introduction
11.5.4 Aspen Revenue in Generic Medicine Business (2019-2024)
11.5.5 Aspen Recent Development
11.6 Fresenius Kabi
11.6.1 Fresenius Kabi Company Detail
11.6.2 Fresenius Kabi Business Overview
11.6.3 Fresenius Kabi Generic Medicine Introduction
11.6.4 Fresenius Kabi Revenue in Generic Medicine Business (2019-2024)
11.6.5 Fresenius Kabi Recent Development
11.7 Pfizer (Hospira)
11.7.1 Pfizer (Hospira) Company Detail
11.7.2 Pfizer (Hospira) Business Overview
11.7.3 Pfizer (Hospira) Generic Medicine Introduction
11.7.4 Pfizer (Hospira) Revenue in Generic Medicine Business (2019-2024)
11.7.5 Pfizer (Hospira) Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Generic Medicine Introduction
11.8.4 Sanofi Revenue in Generic Medicine Business (2019-2024)
11.8.5 Sanofi Recent Development
11.9 Aurobindo
11.9.1 Aurobindo Company Detail
11.9.2 Aurobindo Business Overview
11.9.3 Aurobindo Generic Medicine Introduction
11.9.4 Aurobindo Revenue in Generic Medicine Business (2019-2024)
11.9.5 Aurobindo Recent Development
11.10 Lupin
11.10.1 Lupin Company Detail
11.10.2 Lupin Business Overview
11.10.3 Lupin Generic Medicine Introduction
11.10.4 Lupin Revenue in Generic Medicine Business (2019-2024)
11.10.5 Lupin Recent Development
11.11 Dr. Reddy's
11.11.1 Dr. Reddy's Company Detail
11.11.2 Dr. Reddy's Business Overview
11.11.3 Dr. Reddy's Generic Medicine Introduction
11.11.4 Dr. Reddy's Revenue in Generic Medicine Business (2019-2024)
11.11.5 Dr. Reddy's Recent Development
11.12 Apotex
11.12.1 Apotex Company Detail
11.12.2 Apotex Business Overview
11.12.3 Apotex Generic Medicine Introduction
11.12.4 Apotex Revenue in Generic Medicine Business (2019-2024)
11.12.5 Apotex Recent Development
11.13 Cipla
11.13.1 Cipla Company Detail
11.13.2 Cipla Business Overview
11.13.3 Cipla Generic Medicine Introduction
11.13.4 Cipla Revenue in Generic Medicine Business (2019-2024)
11.13.5 Cipla Recent Development
11.14 ENDO (Par Pharmaceutical)
11.14.1 ENDO (Par Pharmaceutical) Company Detail
11.14.2 ENDO (Par Pharmaceutical) Business Overview
11.14.3 ENDO (Par Pharmaceutical) Generic Medicine Introduction
11.14.4 ENDO (Par Pharmaceutical) Revenue in Generic Medicine Business (2019-2024)
11.14.5 ENDO (Par Pharmaceutical) Recent Development
11.15 Stada Arzneimittel
11.15.1 Stada Arzneimittel Company Detail
11.15.2 Stada Arzneimittel Business Overview
11.15.3 Stada Arzneimittel Generic Medicine Introduction
11.15.4 Stada Arzneimittel Revenue in Generic Medicine Business (2019-2024)
11.15.5 Stada Arzneimittel Recent Development
11.16 Krka Group
11.16.1 Krka Group Company Detail
11.16.2 Krka Group Business Overview
11.16.3 Krka Group Generic Medicine Introduction
11.16.4 Krka Group Revenue in Generic Medicine Business (2019-2024)
11.16.5 Krka Group Recent Development
11.17 Nichi-Iko Pharmaceutical
11.17.1 Nichi-Iko Pharmaceutical Company Detail
11.17.2 Nichi-Iko Pharmaceutical Business Overview
11.17.3 Nichi-Iko Pharmaceutical Generic Medicine Introduction
11.17.4 Nichi-Iko Pharmaceutical Revenue in Generic Medicine Business (2019-2024)
11.17.5 Nichi-Iko Pharmaceutical Recent Development
11.18 Valeant
11.18.1 Valeant Company Detail
11.18.2 Valeant Business Overview
11.18.3 Valeant Generic Medicine Introduction
11.18.4 Valeant Revenue in Generic Medicine Business (2019-2024)
11.18.5 Valeant Recent Development
11.19 Zydus Cadila
11.19.1 Zydus Cadila Company Detail
11.19.2 Zydus Cadila Business Overview
11.19.3 Zydus Cadila Generic Medicine Introduction
11.19.4 Zydus Cadila Revenue in Generic Medicine Business (2019-2024)
11.19.5 Zydus Cadila Recent Development
11.20 Hikma
11.20.1 Hikma Company Detail
11.20.2 Hikma Business Overview
11.20.3 Hikma Generic Medicine Introduction
11.20.4 Hikma Revenue in Generic Medicine Business (2019-2024)
11.20.5 Hikma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.